Psychopharmacology Updates for Prescribers

In this newsletter, we share some tips we bring home from the APA Annual Meeting, which focused on the theme of confronting addiction. We also share key points from an interview on considerations for using broad-spectrum micronutrients in clinical practice, a presentation on key aspects of benzodiazepine prescribing, and practical research summaries on adult psychiatry.

This newsletter provides information about the FDA's recent approval of iloperidone to treat bipolar I disorder in adults. It discusses the drug's effectiveness, recommended dosages, and potential adverse effects. We also share key points from an interview on the principles of psychodynamic psychopharmacology, a presentation on the evidence supporting the application of TMS in the treatment of various psychiatric disorders and its potential side effects, and our practical research summaries of child, adolescent, and adult psychiatry.

The newsletter contains information about the FDA's decision regarding roluperidone, a new medication proposed for treating negative symptoms in schizophrenia. Additionally, it presents key points from a recent interview discussing pharmacologic treatment options for autism spectrum disorder (ASD) and a presentation on how to manage behavioral emergencies with newer options such as dexmedetomidine.

This newsletter provides details about the discontinuation of aducanumab and its associated ENVISION clinical study. The decision was made following a strategic review that identified financial shortcomings as a critical issue. We also share key points from an interview on nociceptive pain syndromes, which have a connection to fibromyalgia; a presentation on lamotrigine, elaborating on its approved uses and potential cardiac adverse effects; and our practical research summaries of child, adolescent, and adult psychiatry.

This newsletter focuses on promising drugs and new applications of known drugs that may play a significant role in mental health treatment by 2024. Each drug is explored along with the available evidence supporting its efficacy. We also share key points on an interview on depression, anxiety, and delirium in patients with cancer; a presentation on psychodynamic psychopharmacology; and our practical research summaries of adult psychiatry (Quick Takes).

This newsletter summarizes all the FDA-approved medication in the psychiatric field for the year 2023. It includes treatments for a wide range of conditions, including Alzheimer's disease, depression, anxiety disorders, and even sexual disorders. We also discuss the treatment of tic disorders in youth, key points from a presentation on insomnia and major depressive disorder (MDD), and our practical research summaries of adult, child, and adolescent psychiatry (Quick Takes and CAP Smart Takes).

In this newsletter, we discuss the recent warning issued by the FDA about the potential health risks associated with using ketamine products in treating an array of psychiatric disorders. We also discuss the efficacy of broad-spectrum micronutrient (BSM) supplementation for psychiatric disorders, key points from a presentation on the use of natural medication, and our practical research summaries of adult, child, and adolescent psychiatry (Quick Takes and CAP Smart Takes).

In this newsletter, we explore the antidepressant gepirone extended release (Exxua), which was recently approved by the FDA for treating major depressive disorder in adults. We also discuss principles for assessing and managing parasomnias triggered by antidepressants, key points from a presentation on psychodynamic psychopharmacology, and our practical research summaries of adult, child, and adolescent psychiatry (Quick Takes and CAP Smart Takes).

In this newsletter, we focus on an essential aspect of suicide prevention: pharmacologic strategies. This comes in the wake of last month’s observance of World Suicide Prevention Day. We also discuss strategies for managing explosive behavior in youth, key points from a presentation on perinatal treatment of bipolar disorder, and our practical research summaries of adult, child, and adolescent psychiatry (Quick Takes and CAP Smart Takes).

This newsletter presents the future of postpartum depression treatment with zuranolone, the first-ever oral treatment option approved by the FDA. Unlike SSRIs, zuranolone may work within days and requires only short-term, 2-week use.  We also discuss a pharmacologic algorithm for OCD, key points from a presentation on what clinicians need to know for using broad-spectrum micronutrients in mental health, and our practical research summaries of adult, child, and adolescent psychiatry (Quick Takes and CAP Smart Takes).

This newsletter presents the findings of a phase 3 trial for donanemab—a groundbreaking drug engineered to battle Alzheimer's disease. The trial results highlight donanemab's promise in decelerating the progression of early-stage Alzheimer's. We also discuss updates on atypical psychopharmacologic strategies for youth, key points from a presentation on pharmacologic therapies for fibromyalgia, and our practical research summaries of adult, child, and adolescent psychiatry (Quick Takes and CAP Smart Takes).

This newsletter presents a selection of evidence-based apps tailored for various psychiatric disorders to enhance conventional therapies and inspire patients to assume control of their mental health outside of clinical settings. We also discuss updates on geriatric psychopharmacology, key points from a presentation on clozapine, and our practical research summaries of adult, child, and adolescent psychiatry (Quick Takes and CAP Smart Takes).